MultiCare Health System

Postherpetic Neuralgia Study - Allergan

Title: A Study of the Safety and Efficacy of AGN-214868 in Patients with Postherpetic NeuralgiaDescription of Study

Purpose: To evaluate how safe and how well subjects tolerate the investigational drug injected under the skin (intra-dermal), in patients with PHN. The study will also evaluate the effect the drug has on the associated chronic pain of PHN.

Who Can Participate?

Diagnosis or Condition: Subjects with Postherpetic Neuralgia lasting more than 9 months

Age: 18 to 80 years old

Sex: Males and Females

To be included patients must:

  • Have had persistent pain following shingles (herpes zoster)
  • Pain can NOT involve the face or scalp
  • Taking only ONE pain medication
  • If a woman, must be postmenopausal or have had a hysterectomy

Visits: Up to 13 clinic visits over 28 Weeks

Stipend: You will be compensated for your time and travel

Principal Investigator: John R. Huddlestone, MD, FAAN

Study Coordinator: Sandra F. Reilley, MD, CPI, 253.403.7440

For more information, contact the Study Coordinator and reference Allergan study.

For more information about this study, click here.

Share With Friends